| Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib … P Hammel, F Huguet, JL van Laethem, D Goldstein, B Glimelius, P Artru, ... Jama 315 (17), 1844-1853, 2016 | 1067 | 2016 |
| Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and … T André, A De Gramont, D Vernerey, B Chibaudel, F Bonnetain, ... Journal of Clinical Oncology 33 (35), 4176-4187, 2015 | 725 | 2015 |
| Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the … J Franko, Q Shi, JP Meyers, TS Maughan, RA Adams, MT Seymour, ... The Lancet Oncology 17 (12), 1709-1719, 2016 | 534 | 2016 |
| Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study B Chibaudel, F Maindrault-Goebel, G Lledo, L Mineur, T André, ... Journal of Clinical Oncology 27 (34), 5727-5733, 2009 | 529 | 2009 |
| Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter … C Tournigand, T André, F Bonnetain, B Chibaudel, G Lledo, T Hickish, ... Journal of clinical oncology 30 (27), 3353-3360, 2012 | 427 | 2012 |
| Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in … S Gourgou-Bourgade, D Cameron, P Poortmans, B Asselain, D Azria, ... Annals of Oncology 26 (5), 873-879, 2015 | 220 | 2015 |
| Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial FC Bidard, F Huguet, C Louvet, L Mineur, O Bouché, B Chibaudel, P Artru, ... Annals of oncology 24 (8), 2057-2061, 2013 | 220 | 2013 |
| Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or … P Hammel, F Huguet, JL Van Laethem, D Goldstein, B Glimelius, P Artru, ... Journal of Clinical Oncology 31 (15_suppl), LBA4003-LBA4003, 2013 | 203* | 2013 |
| Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC) C Neuzillet, S Gaujoux, N Williet, JB Bachet, L Bauguion, LC Durand, ... Digestive and Liver Disease 50 (12), 1257-1271, 2018 | 170 | 2018 |
| Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label … T André, D Vernerey, L Mineur, J Bennouna, J Desrame, R Faroux, ... Journal of clinical oncology 36 (15), 1469-1477, 2018 | 158 | 2018 |
| Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients MC Etienne‐Grimaldi, G Milano, F Maindrault‐Gœbel, B Chibaudel, ... British journal of clinical pharmacology 69 (1), 58-66, 2010 | 146 | 2010 |
| Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for … A Anota, Z Hamidou, S Paget-Bailly, B Chibaudel, C Bascoul-Mollevi, ... Quality of Life Research 24, 5-18, 2015 | 140 | 2015 |
| Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial C Tournigand, B Chibaudel, B Samson, W Scheithauer, D Vernerey, ... The Lancet Oncology 16 (15), 1493-1505, 2015 | 139 | 2015 |
| Body mass index is prognostic in metastatic colorectal cancer: pooled analysis of patients from first-line clinical trials in the ARCAD database LA Renfro, F Loupakis, RA Adams, MT Seymour, V Heinemann, ... Journal of Clinical Oncology 34 (2), 144-150, 2016 | 137 | 2016 |
| Therapeutic strategy in unresectable metastatic colorectal cancer B Chibaudel, C Tournigand, T André, A de Gramont Therapeutic advances in medical oncology 4 (2), 75-89, 2012 | 126 | 2012 |
| Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy G Manceau, S Imbeaud, R Thiébaut, F Liébaert, K Fontaine, F Rousseau, ... Clinical Cancer Research 20 (12), 3338-3347, 2014 | 114 | 2014 |
| Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal … F Maindrault-Goebel, G Lledo, B Chibaudel, L Mineur, T Andre, ... Journal of Clinical Oncology 25 (18_suppl), 4013-4013, 2007 | 112 | 2007 |
| Personalizing survival predictions in advanced colorectal cancer: the ARCAD nomogram project KM Sjoquist, LA Renfro, RJ Simes, NC Tebbutt, S Clarke, MT Seymour, ... JNCI: Journal of the National Cancer Institute 110 (6), 638-648, 2018 | 109 | 2018 |
| Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials … Q Shi, A De Gramont, A Grothey, J Zalcberg, B Chibaudel, HJ Schmoll, ... Journal of Clinical Oncology 33 (1), 22-28, 2015 | 109 | 2015 |
| Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and … T André, H Blons, M Mabro, B Chibaudel, JB Bachet, C Tournigand, ... Annals of oncology 24 (2), 412-419, 2013 | 106 | 2013 |
